Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 1
Submit an article Journal homepage
215
Views
46
CrossRef citations to date
0
Altmetric
Research Article

Level of CD 20-expression and Efficacy of Rituximab Treatment in Patients with Resistant or Relapsing B-cell Prolymphocytic Leukemia and B-cell Chronic Lymphocytic Leukemia

Jolanta Perz Department of Internal Medicine V, University of Heidelberg, Hospitalstr. 3, D-69115, Heidelberg, Germany
,
Julian Topaly Department of Internal Medicine V, University of Heidelberg, Hospitalstr. 3, D-69115, Heidelberg, Germany
,
Stefan Fruehauf Department of Internal Medicine V, University of Heidelberg, Hospitalstr. 3, D-69115, Heidelberg, Germany
,
Manfred Hensel Department of Internal Medicine V, University of Heidelberg, Hospitalstr. 3, D-69115, Heidelberg, Germany
&
Anthony D. Ho Department of Internal Medicine V, University of Heidelberg, Hospitalstr. 3, D-69115, Heidelberg, Germany
Pages 149-151 | Published online: 01 Jul 2009

Citations (46)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Alessandra Tedeschi, Eleonora Vismara, Francesca Ricci, Enrica Morra & Marco Montillo. (2010) The spectrum of use of rituximab in chronic lymphocytic leukemia. OncoTargets and Therapy 3, pages 227-246.
Read now
Marco Montillo, Timo Schinkoethe & Thomas Elter. (2005) Eradication of Minimal Residual Disease with Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients: The Need for a Standard Method of Detection and the Potential Impact of Bone Marrow Clearance on Disease Outcome. Cancer Investigation 23:6, pages 488-496.
Read now
Giovanni D'Arena, Maria Luigia Vigliotti, Rosella Matera, Clelia Musto, Giovanni Iodice, Alfredo Tartarone & Nicola Di Renzo. (2003) Quantitative Evaluation of CD52 Expression in B-Cell Chronic Lymphocytic Leukemia. Leukemia & Lymphoma 44:7, pages 1255-1257.
Read now
Giovanni D'Arena, Nicola Di Renzo, Maura Brugiatelli, Maria L. Vigliotti & Michael J. Keating. (2003) Biological and Clinical Heterogeneity of B-cell Chronic Lymphocytic Leukemia. Leukemia & Lymphoma 44:2, pages 223-228.
Read now

Articles from other publishers (42)

Zhiwei Ang, Luca Paruzzo, Katharina E. Hayer, Carolin Schmidt, Manuel Torres Diz, Feng Xu, Urvi Zankharia, Yunlin Zhang, Samantha Soldan, Sisi Zheng, Catherine D. Falkenstein, Joseph P. Loftus, Scarlett Y. Yang, Mukta Asnani, Patricia King Sainos, Vinodh Pillai, Emeline Chong, Marilyn M. Li, Sarah K. Tasian, Yoseph Barash, Paul M. Lieberman, Marco Ruella, Stephen J. Schuster & Andrei Thomas-Tikhonenko. (2023) Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies. Blood 142:20, pages 1724-1739.
Crossref
Priya Saikumar Lakshmi, Cliff I Oduor, Catherine S Forconi, Viriato M’Bana, Courtney Bly, Rachel M Gerstein, Juliana A Otieno, John M Ong’echa, Christian Münz, Micah A Luftig, Michael A Brehm, Jeffrey A Bailey & Ann M Moormann. (2023) Endemic Burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies. Life Science Alliance 6:5, pages e202101355.
Crossref
Musa Makongoro, Mahmoud Matar Mohammad Abu Rakhey, Yafei Yu, Jianzhi Sun, Guosheng Li, Na He, Samir Ali Abd El-Kaream & Daoxin Ma. (2022) A new case of trisomy 5 with complex karyotype abnormalities in B-cell prolymphocytic leukemia: a case study. Egyptian Journal of Medical Human Genetics 23:1.
Crossref
Timothy M. Pierpont, Candice B. Limper & Kristy L. Richards. (2018) Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy. Frontiers in Oncology 8.
Crossref
Elisabeth Paietta. 2018. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 237 279 .
Mira Tout, Anne-Laure Gagez, Stéphane Leprêtre, Valérie Gouilleux-Gruart, Nicolas Azzopardi, Alain Delmer, Mélanie Mercier, Loïc Ysebaert, Kamel Laribi, Hugo Gonzalez, Gilles Paintaud, Guillaume Cartron & David Ternant. (2016) Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. Clinical Pharmacokinetics 56:6, pages 635-647.
Crossref
Masami Suzuki, Chie Kato & Atsuhiko Kato. (2015) Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies. Journal of Toxicologic Pathology 28:3, pages 133-139.
Crossref
Xinfeng Lin, Hua Zhu, Zheng Luo, Ye Hong, Hong Zhang, Xijuan Liu, Huirong Ding, Huifang Tian & Zhi Yang. (2014) Near-Infrared Fluorescence Imaging of Non-Hodgkin’s Lymphoma CD20 Expression Using Cy7-Conjugated Obinutuzumab. Molecular Imaging and Biology 16:6, pages 877-887.
Crossref
M. LI, X. XIAO, W. ZHANG, L. LIU, N. XI & Y. WANG. (2014) Nanoscale distribution of CD20 on B-cell lymphoma tumour cells and its potential role in the clinical efficacy of rituximab. Journal of Microscopy 254:1, pages 19-30.
Crossref
Chie Kato, Atsuhiko Kato, Kenji Adachi, Etsuko Fujii, Kaori Isobe, Tomochika Matsushita, Takeshi Watanabe & Masami Suzuki. (2013) Anti-Thy-1 Antibody-mediated Complement-dependent Cytotoxicity is Regulated by the Distribution of Antigen, Antibody and Membrane Complement Regulatory Proteins in Rats. Journal of Toxicologic Pathology 26:1, pages 41-49.
Crossref
Elisabeth Paietta. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 241 283 .
Claire Dearden. (2012) B- and T-cell prolymphocytic leukemia: antibody approaches. Hematology 2012:1, pages 645-651.
Crossref
Rangaiah Shashidharamurthy, Erica N. Bozeman, Jaina Patel, Ramneet Kaur, Jeyandra Meganathan & Periasamy Selvaraj. (2011) Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development. Medicinal Research Reviews 32:6, pages 1197-1219.
Crossref
Emilio Iannitto & Claudio Tripodo. (2011) How I diagnose and treat splenic lymphomas. Blood 117:9, pages 2585-2595.
Crossref
Maryalice Stetler-Stevenson & Constance M. Yuan. 2010. Diagnostic Techniques in Hematological Malignancies. Diagnostic Techniques in Hematological Malignancies 51 70 .
Ali Al-Ameri, Mohamad Cherry, Aref Al-Kali & Alessandra Ferrajoli. (2010) The Role of Monoclonal Antibodies in the Management of Leukemia. Pharmaceuticals 3:10, pages 3258-3274.
Crossref
Edward D. Ball & H. Elizabeth Broome. (2010) Monoclonal antibodies in the treatment of hematologic malignancy. Best Practice & Research Clinical Haematology 23:3, pages 403-416.
Crossref
Matt E. Kalaycio, Manisha Kukreja, Ann E. Woolfrey, Jeffrey Szer, Jorge Cortes, Richard T. Maziarz, Brian J. Bolwell, Andreas Buser, Edward Copelan, Robert Peter Gale, Vikas Gupta, Dipnarine Maharaj, David I. Marks, Steven Z. Pavletic, Mary M. Horowitz & Mukta Arora. (2010) Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia. Biology of Blood and Marrow Transplantation 16:4, pages 543-547.
Crossref
John C. Morris & Thomas A. Waldmann. (2009) Antibody-based therapy of leukaemia. Expert Reviews in Molecular Medicine 11.
Crossref
Stéphane Dalle, Sophie Dupire, Stéphanie Brunet-Manquat, Lina Reslan, Adriana Plesa & Charles Dumontet. (2009) In vivo Model of Follicular Lymphoma Resistant to Rituximab . Clinical Cancer Research 15:3, pages 851-857.
Crossref
Adrian Tempescul, Johanna Feuerbach, Jean-Christophe Ianotto, Florence Dalbies, Veronique Marion, Marie-Josée Le Bris, Marc De Braekeleer & Christian Berthou. (2008) A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia. Annals of Hematology 88:1, pages 85-88.
Crossref
Tadeusz Robak. (2008) Treatment of chronic lymphoid leukemias with monoclonal antibodies: current place and perspectives. Drug Development Research 69:7, pages 373-387.
Crossref
Amani Mankaï, Anne Bordron, Yves Renaudineau, Christine Martins-Carvalho, Shinichiro Takahashi, Ibtissem Ghedira, Christian Berthou & Pierre Youinou. (2008) Purine-Rich Box-1–Mediated Reduced Expression of CD20 Alters Rituximab-Induced Lysis of Chronic Lymphocytic Leukemia B Cells. Cancer Research 68:18, pages 7512-7519.
Crossref
Xuhui Zhou, Weiguo Hu & Xuebin Qin. (2008) The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy. The Oncologist 13:9, pages 954-966.
Crossref
Christian Meyer zum Büschenfelde, Yvonne Feuerstacke, Katharina S. Götze, Katrin Scholze & Christian Peschel. (2008) GM1 Expression of Non-Hodgkin's Lymphoma Determines Susceptibility to Rituximab Treatment. Cancer Research 68:13, pages 5414-5422.
Crossref
Falko Fend, Alexandar Tzankov, Karin Bink, Stefan Seidl, Leticia Quintanilla-Martinez, Marcus Kremer & Stephan Dirnhofer. (2008) Modern techniques for the diagnostic evaluation of the trephine bone marrow biopsy: Methodological aspects and applications. Progress in Histochemistry and Cytochemistry 42:4, pages 203-252.
Crossref
Bassem T. Chaar & Paul J. Petruska. (2006) Complete response to alemtuzumab in a patient with B prolymphocytic leukemia. American Journal of Hematology 82:5, pages 417-417.
Crossref
B. H. Davis, J.T. Holden, M.C. Bene, M.J. Borowitz, R.C. Braylan, D. Cornfield, W. Gorczyca, R. Lee, R. Maiese, A. Orfao, D. Wells, B.L. Wood & M. Stetler-Stevenson. (2007) 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: Medical indications. Cytometry Part B: Clinical Cytometry 72B:S1, pages S5-S13.
Crossref
Tom van Meerten, Rozemarijn S. van Rijn, Samantha Hol, Anton Hagenbeek & Saskia B. Ebeling. (2006) Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity. Clinical Cancer Research 12:13, pages 4027-4035.
Crossref
Thomas S. Lin & John C. Byrd. 2006. Oncology. Oncology 1210 1228 .
Marcus Kremer, Leticia Quintanilla-Martínez, Jörg Nährig, Christoph von Schilling & Falko Fend. (2005) Immunohistochemistry in bone marrow pathology: a useful adjunct for morphologic diagnosis. Virchows Archiv 447:6, pages 920-937.
Crossref
Ahmed Absi, Eric Hsi & Matt Kalaycio. (2005) Prolymphocytic leukemia. Current Treatment Options in Oncology 6:3, pages 197-208.
Crossref
M. Stern & R. Herrmann. (2005) Overview of monoclonal antibodies in cancer therapy: present and promise. Critical Reviews in Oncology/Hematology 54:1, pages 11-29.
Crossref
Fabian D. Arditti, Aharon Rabinkov, Talia Miron, Yair Reisner, Alain Berrebi, Meir Wilchek & David Mirelman. (2005) Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate . Molecular Cancer Therapeutics 4:2, pages 325-332.
Crossref
Stefano A. Pileri, Elena Sabattini, Claudio Agostinelli, Laura Bodega, Maura Rossi, Pier Luigi Zinzani & Teresa Marafioti. (2004) Histopathology of B-cell chronic lymphocytic leukemia. Hematology/Oncology Clinics of North America 18:4, pages 807-826.
Crossref
Thomas S. Lin, Mollie Moran, Margaret Lucas, Sharon Waymer, Sara Jefferson, Diane B. Fischer, Michael R. Grever & John C. Byrd. (2004) Antibody therapy for chronic lymphocytic leukemia: a promising new modality. Hematology/Oncology Clinics of North America 18:4, pages 895-913.
Crossref
Peter Hillmen. (2004) Advancing Therapy For Chronic Lymphocytic Leukemia–the Role Of Rituximab. Seminars in Oncology 31, pages 22-26.
Crossref
Thomas S. Lin & John C. Byrd. 2004. Treatment of Leukemia and Lymphoma. Treatment of Leukemia and Lymphoma 127 167 .
Thomas S. Lin, Margaret S. Lucas & John C. Byrd. 2004. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia 269 298 .
Thomas S. Lin, Margaret S. Lucas & John C. Byrd. (2003) Rituximab in B-Cell chronic lymphocytic leukemia. Seminars in Oncology 30:4, pages 483-492.
Crossref
Peter H. Wiernik. 2003. 365 397 .
. (2002) Current Awareness in Hematological Oncology. Hematological Oncology 20:4, pages 189-196.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.